The natural history of perforated marginal ulcers after gastric bypass surgery
Although perforated marginal ulcers (pMU) following Roux-en-Y Gastric Bypass (RYGB) represent a surgical emergency, the epidemiology and outcome of this condition is not well understood. The purpose of this study was to evaluate incidence of pMU following RYGB and assess the natural history of this complication.
The SPARCS administrative database was used to identify patients undergoing RYGB between 2005 and 2010. With the use of a unique identifier, we followed patients up to 2014 for subsequent admission and re-intervention (repair or revision) for perforated MU. Groups were compared using Chi square tests with exact p values based on Monte Carlo simulation, t test with unequal variances, and the Wilcoxon rank-sum test when appropriate.
We identified 35,080 RYGB patients; 292 patients (0.83%) developed pMU 937 (443–1546) days following RYGB [Median (Q1–Q3)]. Among these 292 patients, tobacco use was present in one-third of patients. Repair of the perforation was performed in 115 patients, while anastomotic revision was reported in 64. Patients who underwent revision were more likely to have respiratory complications. Hospital length of stay was significantly longer for patients managed with RYGB revision (Median, Q1–Q3:7, 5–14, vs 6, 4–7, days, p = 0.001). Recurrence of marginal ulcer was common after either intervention (26.09% for repair and 29.69% for revision, p = 0.726).
Following RYGB, the incidence of pMU is small. Anastomotic revision for pMU is associated with prolonged length of stay compared to repair alone. Importantly, recurrence after intervention of pMU is common, suggesting possible value of a routine surveillance program for patients following pMU.
KeywordsRoux-en-Y Gastric Bypass Perforated marginal ulcer
We acknowledge the biostatistical consultation and support provided by the Biostatistical Consulting Core at School of Medicine, Stony Brook University.
No industry or other external funding was used for this research.
Compliance with ethical standards
Dr. Pryor receives honoraria for speaking for Ethicon, Medtronic, Stryker, and Gore; is a consultant for Medicines Company, Merck, and Intuitive, and has ownership interest in Transenterix. Maria S. Altieri, Jie Yang, Donglei Yin, Salvatore Docimo, Andrew Bates, Mark Talamini, Konstantinos Spaniolas have no conflicts of interest or financial ties to disclose.
- 1.Centers for Disease Control, National Center for Health Statistics (2015). https://www.cdc.gov/nchs/fastats/obesity-overweight.htm. Accessed 23 Feb 2017
- 2.New procedure estimates for bariatric surgery: what the numbers reveal. Connect: the official news magazine of ASMBS (2014). http://connect.asmbs.org/may-2014-bariatric-surgery-growth.html. Accessed 14 Dec 2016
- 17.Coblijn UK, Lagarde SM, de Castro SM, Kuiken SD, van Tets WF, van Wagensveld BA (2016) The influence of prophylactic proton pump inhibitor treatment on the development of symptomatic marginal ulceration in Roux-en-Y gastric bypass patients: a historic cohort study. Surg Obes Relat Dis 12(2):246–252CrossRefPubMedGoogle Scholar